Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis - Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction

被引:370
作者
Joosten, LAB
Lubberts, E
Durez, P
Helsen, MMA
Jacobs, MJM
Goldman, M
vandenBerg, WB
机构
[1] UNIV NIJMEGEN HOSP,DEPT RHEUMATOL,NL-6500 HB NIJMEGEN,NETHERLANDS
[2] FREE UNIV BRUSSELS,HOSP ERASMUS,B-1070 BRUSSELS,BELGIUM
来源
ARTHRITIS AND RHEUMATISM | 1997年 / 40卷 / 02期
关键词
D O I
10.1002/art.1780400209
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To examine the role of endogenous interleukin-4 (IL-4) and interleukin-10 (IL-10) and the therapeutic effect of the addition of IL-4 and IL-10 in early and established murine collagen-induced arthritis (CIA). Methods. Murine recombinant IL-4, IL-10, or the combination was given intraperitoneally twice daily from the day of arthritis onset up to 7-10 days of CIA in DBA/1 mice. Anti-IL-4, anti-IL-10, or both antibodies were given intraperitoneally before or after the onset of CIA. The effect of cytokine or anticytokine treatment was monitored visually by macroscopic scoring. Histology and reverse transcription-polymerase chain reaction (RT-PCR) analyses were performed at the end of the treatment period. Results. IL-4 alone did not provoke any effect, IL-10 slightly suppressed the arthritis, but a more pronounced amelioration was found with the combination. This cooperative effect was noted after early treatment but also occurred when the start of treatment was delayed until 1 week after onset. Apart from suppression of macroscopic signs of inflammation, combined treatment with IL-4/IL-10 also reduced cellular infiltrates in the synovial tissue and caused pronounced protection against cartilage destruction. Moreover, levels of mRNA for tumor necrosis factor alpha (TNF alpha) and IL-1 were highly suppressed both in the synovial tissue and in the articular cartilage. In contrast, levels of IL-1 receptor antagonist (IL-1Ra) mRNA remained elevated, which suggests that the mechanism of protection may be related to suppressed production of TNF alpha and IL-1, with concomitant up-regulation of the IL-1Ra/IL-1 balance. However, accelerated onset of CIA and increased severity could be achieved with neutralizing anti-IL-10 antibodies. This expression could be further optimized with a combination of anti-IL-4 and anti-IL-10 antibodies, although anti-IL-4 alone was without effect. Conclusion. Our data are consistent with a dominant role of IL-10 in the natural suppression of arthritis expression, whereas combined treatment with IL-4 and IL-10 appears of potential therapeutic value, not only at the onset, but also in established arthritis.
引用
收藏
页码:249 / 260
页数:12
相关论文
共 58 条
[41]   INTERLEUKIN-10 INHIBITS THE INDUCTION OF MONOCYTE PROCOAGULANT ACTIVITY BY BACTERIAL LIPOPOLYSACCHARIDE [J].
PRADIER, O ;
GERARD, C ;
DELVAUX, A ;
LYBIN, M ;
ABRAMOWICZ, D ;
CAPEL, P ;
VELU, T ;
GOLDMAN, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (10) :2700-2703
[42]  
RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334
[43]  
ROSENBAUM JT, 1995, J IMMUNOL, V155, P4090
[44]  
SALERNO A, 1995, IMMUNOLOGY, V84, P404
[45]   A SENSITIVE AND SPECIFIC BIOASSAY FOR THE DETECTION OF HUMAN INTERLEUKIN-10 [J].
SCHLAAK, JF ;
SCHMITT, E ;
HULS, C ;
ZUMBUSCHENFELDE, KHM ;
FLEISCHER, B .
JOURNAL OF IMMUNOLOGICAL METHODS, 1994, 168 (01) :49-54
[46]   NATURE AND SPECIFICITY OF THE IMMUNE-RESPONSE TO COLLAGEN IN TYPE-II COLLAGEN-INDUCED ARTHRITIS IN MICE [J].
STUART, JM ;
TOWNES, AS ;
KANG, AH .
JOURNAL OF CLINICAL INVESTIGATION, 1982, 69 (03) :673-683
[47]  
SUGIYAMA E, 1995, J RHEUMATOL, V22, P2020
[48]   INVOLVEMENT OF ENDOGENOUS TUMOR-NECROSIS-FACTOR-ALPHA AND TRANSFORMING GROWTH-FACTOR-BETA DURING INDUCTION OF COLLAGEN TYPE-II ARTHRITIS IN MICE [J].
THORBECKE, GJ ;
SHAH, R ;
LEU, CH ;
KURUVILLA, AP ;
HARDISON, AM ;
PALLADINO, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (16) :7375-7379
[49]   AUTOIMMUNITY TO TYPE-2 COLLAGEN - EXPERIMENTAL-MODEL OF ARTHRITIS [J].
TRENTHAM, DE ;
TOWNES, AS ;
KANG, AH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1977, 146 (03) :857-868
[50]  
VANDENBERG WB, 1994, CLIN EXP IMMUNOL, V95, P237